Compare COOK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | PLX |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 204.9M |
| IPO Year | 2021 | 1998 |
| Metric | COOK | PLX |
|---|---|---|
| Price | $0.91 | $1.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $2.04 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 675.8K | 560.5K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $582,799,000.00 | $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $25.34 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $0.71 | $1.32 |
| 52 Week High | $3.31 | $3.10 |
| Indicator | COOK | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 38.71 |
| Support Level | $0.71 | $1.68 |
| Resistance Level | $0.84 | $1.78 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.08 | 43.48 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.